After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Akero Therapeutics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Akero Therapeutics Inc is $2.33B. A total of 0.64 million shares were traded on the day, compared to an average of 499.32K shares.
In the most recent transaction, Yale Catriona sold 15,485 shares of AKRO for 32.62 per share on Nov 01 ’24. After the transaction, the Chief Development Officer now owns 74,158 company shares. In a previous transaction on Oct 30 ’24, Yale Catriona sold 4,515 shares at 32.53 per share. AKRO shares that Chief Development Officer owns now total 74,158.
Among the insiders who bought shares, CATRIONA YALE acquired of 29,074 shares on Nov 01 ’24 at a per-share price of $30.83. In another insider transaction, Cheng Andrew sold 63,539 shares at $31.53 per share on Oct 18 ’24. Company shares held by the President and CEO now total 605,417.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, AKRO has a high of $37.00 and a low of $12.96.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. AKRO’s latest balance sheet shows that the firm has $188.26M in Cash & Short Term Investments as of fiscal 2021. There were $1.52M in debt and $25.13M in liabilities at the time. Its Book Value Per Share was $11.53, while its Total Shareholder’s Equity was $169.11M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AKRO is Buy with a score of 4.82.
